Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 5/20 | 0.89 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.89 |
| ▸ | HTR3B | O95264 | 3/20 | 0.89 |
| ▸ | HTR3A | P46098 | 3/20 | 0.89 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.89 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.89 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.89 |
| ▸ | LTA4H | P09960 | 4/20 | 0.72 |
| ▸ | HTR1A | P08908 | 3/20 | 0.62 |
| ▸ | HTR1B | P28222 | 2/20 | 0.62 |
| ▸ | HTR1D | P28221 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.54 |
| ▸ | HTR7 | P34969 | 2/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410870 | 0.94 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL234280 | 0.94 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL2302729 | 0.93 | ADRB1 (0.96) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Bromide SCHEMBL11070661 | 0.93 | ADRB1 (0.96) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Piperazine SCHEMBL8590918 | 0.93 | ADRB1 (0.96) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL1724680 | 0.93 | ADRB1 (0.96) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL9058690 | 0.89 | ADRB1 (0.89) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5237992 | 0.88 | ADRB1 (0.86) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7171062 | 0.88 | ADRB1 (0.86) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL7921830 | 0.88 | ADRB1 (0.86) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750012-B2 | Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2010-07-06 | — | — | US | disclosed |
| US-7750012-B2 | Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2010-07-06 | — | — | US | disclosed |
| US-7750012-B2 | Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2010-07-06 | — | — | US | disclosed |
| EP-1968961-A2 | BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | Decode Genetics EHF (IS) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007078335-A2 | BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS, EHF. (IS) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007078335-A2 | BIARYL NITROGEN HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS, EHF. (IS) | 2007-07-12 | — | — | WO | disclosed |
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149544-A1 | BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTC4S, LTB4R | ADRB1 1432/4885HTR3E 1632/4885HTR3B 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.